Diffusion MRI in prostate cancer with ultra‐strong whole‐body gradients

Malwina Molendowska, Marco Palombo, Kieran Foley, Krishna Narahari, Fabrizio Fasano, Derek K. Jones, Daniel C. Alexander, Eleftheria Panagiotaki, Chantal M. W. TaxNMR 2024 · DOI

TL;DR

This study demonstrates the feasibility of using ultra-strong whole-body MRI gradients (300 mT/m) for prostate cancer imaging. By employing these powerful gradients, researchers achieved significant improvements in signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR), leading to better lesion visibility and potentially enhancing early detection and diagnostic precision for prostate cancer.

What Problem Does This Paper Address?

Prostate cancer (PCa) detection and classification heavily rely on diffusion-weighted magnetic resonance imaging (dMRI). Current clinical dMRI protocols, however, are hampered by a low signal-to-noise ratio (SNR), especially at the higher b-values (≥ 1.4 ms/µm²) recommended by PI-RADS guidelines. This low SNR is primarily due to the prolonged echo times (TEs) required by the limited gradient power (40-80 mT/m) of conventional MRI systems. While ultra-strong gradient systems have shown promise in brain imaging, their application to prostate imaging, with its unique challenges like susceptibility artifacts, has been limited. This paper aims to bridge this gap by investigating the feasibility and benefits of using a 300 mT/m whole-body gradient system for prostate dMRI.

Methods

The researchers utilized a research-only 3T Siemens Connectom MRI scanner equipped with a powerful 300 mT/m gradient system. They compared dMRI acquisition protocols using these strong gradients against protocols mimicking clinical gradient strengths. Key aspects of their methodology included:

  • Protocol Design: Multiple dMRI protocols (P1-P3) were designed to reflect different gradient strengths (300, 80, and 40 mT/m) while aiming for the shortest achievable echo times (TEs) for each. Additional protocols (P4-P6) were used to explore even higher b-values.
  • Data Acquisition: A cohort of healthy men and men diagnosed with prostate cancer were scanned.
  • Artifact Assessment and Correction: The study specifically assessed and evaluated correction methods for artifacts that are often amplified by stronger gradients.
  • Quantitative Analysis: SNR and contrast-to-noise ratio (CNR) were statistically analyzed to determine the impact of protocol and b-value.
  • Qualitative Assessment: An experienced radiologist evaluated the diagnostic quality of the images using a 5-point Likert scale and an adapted PI-QUAL scoring system.

Datasets

The study used data from a cohort of:

  • Four healthy men (age range: 46-64 years)
  • Six patients diagnosed with prostate cancer (age range: 67-74 years), specifically those in the Active Surveillance Programme with peripheral zone (PZ) prostate cancer confirmed by biopsy.

No new benchmark datasets were introduced; the study focused on evaluating existing imaging techniques on a novel hardware configuration.

Key Insights and Ideas

  • Stronger gradients unlock higher b-values: The core idea is that stronger gradients allow for shorter echo times (TEs) at higher b-values. This is crucial because higher b-values are known to improve lesion visibility in dMRI.
  • Prostate's unique challenges: Unlike the brain, the prostate presents different susceptibility artifacts due to the presence of gas in the rectum and varying tissue types. This necessitates careful consideration of artifact correction strategies.
  • SNR and CNR are game-changers: The study highlights that the primary benefit of stronger gradients is a significant boost in SNR and CNR, which directly translates to better image quality and potentially more accurate diagnoses.
  • Artefacts are manageable: While stronger gradients can amplify artifacts, the study demonstrates that these can be effectively corrected, negating the concern that artifacts would outweigh the benefits.

Key Results

  • Significant SNR gain: The use of strong gradients for prostate dMRI resulted in a significant gain in SNR per unit time compared to clinical gradients.
  • Improved CNR: A 1.6-2.1-fold increase in lesion-to-healthy tissue CNR was observed with the stronger gradients.
  • Diagnostic quality: Images acquired with higher b-values and stronger gradients were rated as having high diagnostic quality, with a radiologist preferring the protocol with the strongest gradients (P1) due to its improved diffusion contrast.
  • Feasibility confirmed: The study successfully demonstrated the feasibility of using a 300 mT/m whole-body scanner for prostate cancer imaging without any reported adverse physiological effects.
  • Artefact correction effectiveness: Despite more pronounced artifacts, satisfactory correction was achieved, leading to smoother and less biased parameter maps, especially with shorter TEs.

Limitations and Future Work

  • Small Sample Size: The study acknowledges its small sample size and the lack of demographic matching between groups.
  • Low-Grade Cancers: The cohort primarily consisted of patients with low-grade prostate cancer. The benefits of higher b-values might be even more pronounced in higher-grade cancers.
  • TE and Diffusion Time Dependence: The study focused on achieving the highest b-value per TE for different gradient strengths, potentially overlooking the nuanced interplay of diffusion time dependence and transverse relaxation effects.
  • Radiologist Evaluation: The diagnostic utility was assessed by a single radiologist.
  • Future Work: The authors suggest future work to establish clinically feasible minimal protocols for next-generation MRI scanners. Further investigation into optimizing TE and diffusion time for maximum contrast and differentiating low-grade from high-grade lesions is also recommended. Additionally, exploring more advanced microstructural acquisition sequences and analysis methods tailored for strong gradient data is proposed.

Summary updated

Abstract

Diffusion-weighted MRI (dMRI) is universally recommended for the detection and classification of prostate cancer (PCa), with PI-RADS recommendations to acquire b-values of ≥1.4 ms/μm<sup>2</sup>. However, clinical dMRI suffers from a low signal-to-noise ratio (SNR) as the consequence of prolonged echo times (TEs) attributable to the limited gradient power in the range of 40-80 mT/m. To overcome this, MRI systems with strong gradients have been designed but so far have mainly been applied in the brain. The aim of this work was to assess the feasibility, data quality, SNR and contrast-to-noise ratio (CNR) of measurements in PCa with a 300 mT/m whole-body system. A cohort of men without and with diagnosed PCa were imaged on a research-only 3T Connectom Siemens MRI system equipped with a gradient amplitude of 300 mT/m. dMRI at high b-values were acquired using high gradient amplitudes and compared with gradient capabilities mimicking clinical systems. Data artefacts typically amplified with stronger gradients were assessed and their correction evaluated. The SNR gains and lesion-to-healthy tissue CNR were statistically tested investigating the effect of protocol and b-value. The diagnostic quality of the images for different dMRI protocols was assessed by an experienced radiologist using a 5-point Likert scale and an adapted PI-QUAL scoring system. The strong gradients for prostate dMRI allowed a significant gain in SNR per unit time compared with clinical gradients. Furthermore, a 1.6-2.1-fold increase in CNR was observed. Despite the more pronounced artefacts typically associated with strong gradients, a satisfactory correction could be achieved. Smoother and less biased parameter maps were obtained with protocols at shorter TEs. The results of this study show that dMRI in PCa with a whole-body 300-mT/m scanner is feasible without a report of physiological effects, SNR and CNR can be improved compared with lower gradient strengths, and artefacts do not negate the benefits of strong gradients and can be ameliorated. This assessment provides the first essential step towards unveiling the full potential of cutting-edge scanners, now increasingly becoming available, to advance early detection and diagnostic precision.
BibTeX
@inproceedings{molendowska2024diffusion,
  author = {Malwina Molendowska and Marco Palombo and Kieran Foley and Krishna Narahari and Fabrizio Fasano and Derek K. Jones and Daniel C. Alexander and Eleftheria Panagiotaki and Chantal M. W. Tax},
  title = {{Diffusion MRI in prostate cancer with ultra‐strong whole‐body gradients}},
  booktitle = {NMR},
  year = {2024},
  doi = {10.1002/nbm.5229},
}
Figure